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ABSTRACT
A complex set of European regulations aims to facilitate
regenerative medicine, harmonizing good clinical and
manufacturing standards and streamlining ethical approval
procedures. The sociology of standardization has elaborated
some of the eﬀects of regulation but little is known about
how such implementation works in practice across
institutions and countries in regenerative medicine. The
eﬀects of transnational harmonization of clinical trial
conduct are complex. A long-term ethnographic study
alongside a multinational clinical trial ﬁnds a range of
obstacles. Harmonization standardizes at one level, but
implementing the standards brings to the fore new
layers of diﬀerence between countries. Europe-wide
harmonization of regulations currently disadvantages low-
cost clinician-lead research in comparison to industry-
sponsored clinical trials. Moreover, harmonized standards
must be aligned with the cultural variations in everyday
practice across European countries. Each clinical team must
ﬁnd its own way of bridging harmonized compulsory
practice with how things are done where they are,
respecting expectations from both patients and the local
hospital ethics committee. Established ways of working
must further be adapted to a range of institutional and
cultural conventions that aﬀect the clinical trial such as
insurance practices and understandings of patient
autonomy. An additional ﬁnding is that the speciﬁc
practical roles of team members in the trial aﬀect their
evaluation of the importance of these challenges. Our
ﬁndings lead to conclusions of wider signiﬁcance for the
sociology of standards concerning how regulation works
and for medical sociology about how trial funding and
research directions in stem cell medicine intersect.
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Standardization is an active, time- and resource-intensive process. Depending on the
standard, building standard-based societies may require integration of many diﬀerent
levels: from national cultures with their moral orders to institutions with their conven-
tions of work practices, organizations, and multiple layers of technologies.…Very few
standards work as intended by the designers of standards because they are tinkered
with, whether slightly or fundamentally. It would be wrong to consider these standards
as failures because a standard’s ﬂexibility is often key to its success. (Timmermans and
Epstein, 2010, p. 81)
1. Introduction
There is much public debate and professional concern about the costs and
amount of time it takes for new therapeutics to come into the clinic. European
regulations aim to address this problem by harmonizing the standards for clini-
cal trials that provide evidence for the eﬀectiveness of new treatments across all
EU countries. Standardization aims to simplify and speed up innovation and
approval processes in order to facilitate the rollout of new therapeutics across
the EU.
Randomized control trials (RCTs) are widely used as a gold standard in
medical research, although the limits of methodology have been criticized
over the past decades (Cartwright, 2007; Will, 2007), and other protocols to
test new therapies have been developed, such as hospital exemptions in the
case of rare diseases (Salter et al., 2014). But the RCT is still the dominant
method of scientiﬁc validation in the clinic. To test a new drug or treatment
on thousands of patients, inclusion criteria for a trial are deﬁned, according to
which the patients must be similar in relevant characteristics. In relation to
these internal validity criteria, the proportional success of the new treatment
can be measured. The trial protocol narrowly deﬁnes the group of trial patients
approached, how the tested medical innovation is administered and how its
clinical eﬃcacy is monitored. Half of the patients receive the new treatment,
the other half are treated according to the best current standard care. All patients
are followed up according to the agreed protocol.
An inevitable tension exists between keeping the patient group as narrowly
deﬁned as possible (internal validity) and showing the eﬃcacy of the new treat-
ment across diﬀerent communities (external validity). The internal validity cri-
terion has been prioritized in regulations and standards to harmonize
multinational trials in the EU. Striking the balance between keeping a trial feas-
ible and speciﬁc for scientiﬁc validity and producing generalizable results is
tricky and open to critique. Patient groups and treatment protocols must be
suﬃciently standardized to measure the clinical eﬃcacy of the new treatment,
i.e. the trial outcome, whilst including a varied patient population, ideally
from diverse socio-economic groups and diﬀerent cultures. This article
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highlights how diﬀerent cultural conventions and practices intersect and aﬀect
the pragmatic running of a trial, not least in terms of time and cost.
The trial reported on will be referred to as BAMI.1 BAMI is an ongoing phase
III clinical trial conducted across 10 EU countries. Our sociological research
segment, entitled ‘Toward Harmonized Ethical Standards’, work package 7 in
BAMI, concerns the eﬀects of uniﬁed protocols on trial conduct across the par-
ticipating clinics, especially the hurdles the teams have had to overcome in order
to gain trial approval and start recruiting patients to the trial. The focus on the
implementation of the trial and the empirical ﬁndings emphasizes that recruit-
ing the required patients for such a trial may itself be a matter of the success of
professional clinical practice on top of the clinical eﬃcacy of the trialled treat-
ment, the success of which cannot be assessed at the time of writing.
This article addresses the following questions:
. How do common trial protocols and approval processes aﬀect work locally?
. What were the national-level implications of aligning every team’s actions to
follow a set of shared international rules?
. What cultural diﬀerences have aﬀected BAMI?
Our ﬁndings illustrate that multinational trials are very diﬃcult to conduct in
practice, even if a shared regulatory framework is in place. European countries
diﬀer vastly in health care provision and insurance systems, but also in routine
patient–doctor interactions, language, aspects of lifestyle and the role of the
family in medical decisions. However, they share the same routine treatment
for acute myocardial infarction (AMI) and how it is administered.2 Concerning
clinical practice, a trial such as BAMI should thus be easy to implement—given
that EU regulation streamlines the process. Yet the inﬂuence of cultural diﬀer-
ences has become an important problem in running the trial.
The new EU regulations on the implementation of clinical trials bring to the
fore a novel array of problems regarding cultural diﬀerences between trial
locations. Multinational trials have to align each participating team to the
same set of rules of conduct. This means that customs of place or institutional
arrangement have to be either altered locally or passed on to every other parti-
cipating country.
Our conclusion points out two aspects of wider signiﬁcance for the sociology
of standards and regulation. The ﬁrst concerns the particular diﬃculties facing
staﬀ managing highly regulated multinational academic trials; the second, the
intersection of trial funding and research directions in stem cell medicine.
The eﬀects of the new harmonized regulations are poorly understood and the
lack of uptake of the Voluntary Harmonization Procedure (VHP) by industry
trial sponsors troubles EU policy-makers. Following standardization, cultural
diﬀerences previously negligible to multinational clinical trial practice can
delay or disrupt trials. This challenges the general endorsement of regulatory
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harmonization as a method of achieving faster clinical translation of the science.
It also brings to light a theoretical question concerning the power of select stan-
dardization as a technique to reshape particular practices woven into the
complex web of multiple diﬀerences in and between nations and communities.
Below we shall provide some background to the debate on harmonized regu-
lation and standards in biomedical innovation and introduce our methodology,
before we present ﬁndings on cultural diﬀerences—especially problems arising
from varied practices of insuring patients and the ways of managing language
and communication with patients.
2. Analytical Perspectives
Standardization has been a key instrument for shaping Europe as a uniﬁed
economic area across which innovations can be rolled out. The beneﬁts of
standards for European industries are extensive and include helping manufac-
turers reduce costs, anticipate technical requirements, increase production
capacity and markets and speed up processes of innovation. The European
Commission endorses these positive eﬀects of standards in areas such as
trade, the creation of a single market for products and services and inno-
vation (European Commission, 2016).3
Social science and, more recently, Science and Technology Studies in particu-
lar, have taken to examining standards and regulation. Susan Leigh Star’s studies
from the 1990s (Star, 1991, 1995; Bowker and Star, 1999; Lampland and Star,
2009) laid the foundation for a critical sociology of standardization explored
further by many scholars, including Stefan Timmermans and Marc Berg, on
whose ﬁndings we draw. Timmermans and Steven Epstein published a review
of the topics covered in the sociology of standards and standardization (2010),
distinguishing between design standards and standardization of processes and
the speciﬁc challenges encountered in standardizing clinical practices of diagno-
sis and treatment. They highlight problems concerning the implementation of
procedural standards, the unpredictability of outcomes and side eﬀects and
the role of experts and professional interests in standard setting. ‘To coordinate
diverse interests and activities, standards necessarily delegate some residual
work that requires active participation and submission of people to the stan-
dard’s directives. Tinkering, repairing, subverting or circumventing prescrip-
tions of the standards are necessary to make standards work’ (p. 81).
Adding to this discussion of standardization, which is often quite abstract, our
case study examines how standardization of cell therapy research in Europe
aﬀects clinical trial implementation and how local practices are adapted in
order to comply to these standards, making them work. The overlapping sets
of existing standards encountered in this multinational trial involve not only
diﬀerences in health care system organization across Europe and other related
institutions, but also the great diﬀerences in cultural and national attitudes
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towards stem cell research, which in turn have received a lot of attention in lit-
erature (see, for example, Bender et al., 2005; Jasanoﬀ, 2005; Salter, 2007; Bel-
trame, 2014). Following wide-ranging harmonization of these regulations of
research, however, new layers of diﬀerence between institutional practices
from both within and outside the clinic and the laboratory have been found
to aﬀect stem cell clinical trial conduct and it is these cultural diﬀerences and
how they aﬀect practice at the stage of implementation that we focus on.
Biomedical innovation is, in some aspects, a special area of standardization
because its objective is to improve human medical care and thus it is charged
with expectations beyond mere economic beneﬁt. The research ﬁeld is often
seen as critical for individual well-being and future material and social well-
being in advanced economies. Common standards have accompanied the devel-
opment of biomedicine and have been increasingly formalized from professional
standards to mandatory oﬃcial regulations (Cambrosio et al., 2009). A European
platform for RCTs in cell therapy and regenerative medicine has been developed.
Decisions regarding RCTs are shaped by both risk awareness and risk avoidance.
These include technological and economic risks as well as risks regarding the
eﬃcacy of therapies (Faulkner et al., 2008).
Annually, between 4,000 and 6,000 applications for randomized clinical trials
are submitted to ethics committees across Europe (European Commission,
2009). The variation in assessment of these applications has led to concerns
about the future of clinical trials (Hartmann and Hartmann-Vareilles, 2006;
Cressy, 2010; Hunter, 2011). Member states set up competent authorities to
approve clinical trials with their own regulations for monitoring Good Clinical
Practice (GCP), reporting serious adverse events and insuring trials (Hartmann,
2012). Thus, the ethical approval procedures for the same scientiﬁc clinical trial
protocol often require country-speciﬁc alterations to that protocol.
In order to overcome this diversity, the EU Clinical Trials Directive (Euro-
pean Commission, 2001) streamlined rules of assessing clinical trial applications
across member states. The aim was to foster equality in patient care and treat-
ment standards, and the timely implementation of future therapies (European
Commission, 2007; Garattini, 2009).
The BAMI trial has to follow these procedures and regulations. In addition,
using stem cells, BAMI also has to comply with the regulations of the European
Tissue and Cells Directive (European Commission, 2004). New regulation is
often ambiguous when ﬁrst implemented. Stephens and colleagues have intro-
duced a notion of ‘never-ending regress whereby scientists have to provide
increasingly more guarantees that protocols have been followed, standards
reached and maintained, and rules adhered to’ (Stephens et al., 2013, p. 346).
That was the case also with the EUTCD, which was complemented with two
technical directives in 2006 that reﬁned which practices are in line with it the
EUTCD and its Good Manufacturing Practice (GMP) and Advanced Therapy
Medicinal Product standard.
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Empirical studies have shown that the directive had in practice been
implemented diﬀerently in diﬀerent European countries (Weber et al., 2010;
Veerus et al., 2014), which aﬀected clinical trials similar to BAMI (Wilson-
Kovacs et al., 2010). Wilson-Kovacs and colleagues have shown that managing
ambiguous new regulations and sorting out their application is a practical
accomplishment. They compared UK and German implementation rules of
the EUTCD and found that the implementation practice in the UK enabled
and required UK-based stem cell researchers to negotiate with the regulator
the status of a speciﬁc use of cells. In Germany, the implementation rules
were applied more uniformly and strictly, requiring high laboratory processing
standards, which led to the widespread upgrading of laboratories years before
the uniﬁed implementation rules the EUTCD put in force in 2010 forced all
laboratories in Europe working with human tissues and cells to upgrade and
comply with new higher standards as well.
The harmonized implementation rules for the EUTCD can be seen as pre-
venting further such negotiations and ending the regulatory regress. Since that
step, all trials using stem cells in innovative ways and in non-homologous
tissues have to apply Advanced Therapy Investigative Medicinal Products
(ATIMP) standards of GMP.
For a multinational trial this means detailed monitoring practices have to be
in place to make sure that all research partners are fully compliant with the trial
protocol. The BAMI trial protocol had to be approved by the UKMedical Health
Research Agency, acting for the European Medicines Agency, which oversees the
implementation of the Directive.
ATIMP compliance had severe consequences for BAMI, aﬀecting its logistics
and ﬁnancial position, and undermining the commitment of some partners to
remain active in the trial. Several partners (and thus countries) dropped out
for diﬀerent reasons, believing that the trial was unattractive or unfeasible
under these conditions. The positive goals of these regulations and the problems
they bring can be described through three diﬀerent dimensions: (a) increasing
scientiﬁc eﬃcacy, (b) timely patient recruitment, and (c) problems involved in
getting various everyday practices to align the best clinical practice with local
cultural expectations (what we call ‘cultural issues’). These three aspects are
intertwined, as will be explained below before we concentrate on the presen-
tation of our ﬁndings regarding dimension (c). For this analysis, we draw on
the theoretical concepts developed in the sociology of regulation and the existing
discussion of clinical trials in regenerative medicine in medical sociology.
2.1. Scientiﬁc Eﬃcacy in Clinical Trials
Why, one might ask, would anyone opt to conduct something as tightly controlled
as a clinical trial across several countries? Problems due to diﬀerent traditions,
health care systems and so on, will almost inevitably arise—which could be
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reduced, if not avoided, by choosing a location as homogenous as possible.
However, the fact that a new drug or treatment works in one local social context
does not show its general clinical eﬃcacy. The generalization from a trial neglects
local factors inﬂuencing treatment outcome—clinical trial results do not readily
apply to all humans (Rothwell, 2005; Petryna, 2009; Will and Moreira, 2010).
Many aspects of standard patient care vary vastly between rich and poor
countries, and between cities and rural areas. Similarly, nutritional factors, life-
style habits, general socio-economic conditions, the involvement of non-pro-
fessional family carers and so on, can inﬂuence patient recovery. Such cultural
factors cannot be standardized or measured in a trial protocol, and consequently,
ﬁndings from only one speciﬁc health care environment and cultural context are
not readily generalizable. Clinical trial ﬁndings need to be validated trans-cultu-
rally. The distinction between internal and external validity (Campbell and
Stanley, 1963) addresses this epistemological issue. The utility and validity of
RCTs has further been challenged because pharmaceutical companies focus
on ﬁrst-world health care issues (Nwobike, 2006), and stem cell therapies
mostly target lifestyle-related diseases of the wealthy (Anele, 2006).
Globalization has highlighted the problems with external validity. For reasons
of fairness, new therapies should be developed and made available to people
regardless of where they live. This ethical and epistemological problem has an
economic side, too. If the validity of a trial is limited, so is the health utility of
the drug or intervention and the potential gain for pharmaceutical businesses
and the wider economy (Sunder Rajan, 2010). It matters for all stakeholders
that the tested stem cell treatment is eﬀective despite the vast diﬀerences in
disease appearance, in economic conditions, and in the cultural practices that
constitute and intersect with health care provision.
2.2. Patient Recruitment and Disease Speciﬁcities
A second parallel development shaping the need for regulatory standardization
is the increasing need for very large populations to recruit participants for clini-
cal trials (Anderson, 2003; Epstein, 2007). Current STS scholarship discusses this
issue in relation to rare or orphan diseases (Hollak et al., 2016), yet, even for very
common conditions such as AMI, recruitment for a large trial can be an issue.
The biomedical sciences have increasingly perceived diﬀerences within what
previously seemed to be just one disease.
Treatments for common diseases in the West have improved greatly over the
past decades and current science targets more and more narrowly deﬁned sub-
types of health conditions. If a treatment is tested not on all patients with breast
cancer or AMI but only on those with a rather speciﬁc form of the condition, it
becomes harder to ﬁnd the thousands of patients needed for a phase III clinical
trial in a patient population. This numerical issue is heightened in RCTs where
half of the patients receive standard treatment.
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Moreover, RCTs must proceed quickly. They cannot go on for a decade or
more, as any improvement to the standard of care in the meantime would
change how patients ought to be cared for and thus undermine either the clinical
or epistemological validity of the trial. Although a major cause of death in Europe,
ﬁnding many AMI patients with severely restricted heart function after primary
coronary angioplasty in 11 European countries over three years, even if through
a large network of clinics, seemed a challenging undertaking before BAMI even
started. None of the clinicians in the trial deemed it feasible to recruit the
patient number needed in clinics in the UK, Spain, Italy or Germany alone.
2.3. The Relevance of Cultural Diﬀerences Within and Beyond the Clinical
Institutions
Present concepts and theoretical literature often regard harmonized regulation as
the pathway to more shared practice. However, in that very process of standardiz-
ation, previously unproblematic cultural diﬀerences between countries become pro-
blematic. Over the past decade, an expansive body of literature in STS has illustrated
the importance of regulation in biomedicine (Cambrosio et al., 2006; Timmermans
and Epstein, 2010). Cambrosio and colleagues dedicated a special issue of Social
Studies of Science to their concept of regulatory objectivity and biomedical conven-
tions (Cambrosio et al., 2009). Helpful analysis on the diﬃculties of agreeing and
implementing standards that can be implemented with the desired eﬀects are pro-
vided by Patrick Castel in oncology research in France (2009), and by Linda Hogle’s
reﬂections on pragmatic objectivity in the standardization of engineered tissues in
the US (2009). Other detailed studies focussed on European regulatory policies
regarding stem cell research and medicine (Salter, 2007; Salter and Salter, 2013),
and the spread of ethical governance via regulation in non-Western countries
(e.g. Waldby and Salter, 2008; Rosemann and Sleeboom-Faulkner, 2016).
Timmermans and Epstein argue that the sociology of standards has shown
that
Standardization is an active process that aspires to stability and order. Any order is a
hard-won achievement that requires the submission of diverse actors. Standardization
consists of building a society around a standard with an implied script that brings
people and things together in a world already full of competing conventions and stan-
dards. (2010, p. 84)
The recent systematic approach to streamlining regulations for clinical trials
(described above), the use of cells and tissues in science and medicine, as well as
the requirement for national competent authority approval, all aim at compre-
hensive regulation of the biomedical sector in Europe—which is already shaped
by national regulations and local practices of compliance, but also diverse health
care environments, ethics and attitudes to what is good medical care. Thus, in
everyday clinical practice these European regulations intersect with a range of
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standards and cultural conventions in diverse areas of social organization. The
standard neither encounters nor produces a standardized world.
In order to ﬁt diverse practice into this levelled regulatory plane, the actors
need to develop creative solutions in order to achieve compliance with the Euro-
pean regulations and national and local expectations and practices. These local
solutions vary according to the diﬀerently organized institutions, expectations
and practices in the participating national cultures. Harmonization achieves
shared practice of all trial practitioners in all the details standardized, yet via
diﬀerent adaptations of routine and locally compliant practice. This tinkering
and active problem-solving is essential for running methodologically credible
trials across cultures and nations with diﬀerent institutional settings.
Some major problems BAMI encountered arose directly from regulation
(Hauskeller and Baur, 2017), yet other problems did not arise from regulation
per se, but from its implementation across diverse interrelated conventions
and practices at national and regional levels. Below we report on how standard-
ization emphasizes the impact of cultural diﬀerences not directly related to the
clinical protocol on trial conduct. We discuss what, from the clinical perspective,
appear to be largely ‘external’ factors. They are, however, so closely entangled
with clinical practice that they can uphold or disrupt the timely implementation
and daily running of a clinical trial. Yet they are outside the scope of regulations
for the clinical environment and are unlikely to become subject to standardiz-
ation any time soon. External factors include insurance practices, and attitudes
to patient consent and to expert-client communication and responsibilities.
BAMI had to comply with formal regulations such as ATIMP but it also was
the ﬁrst large trial to use the new VHP. This procedure promises to reduce regu-
latory hurdles before patient recruitment can begin (Lemaire and Baeyens, 2002;
Baeyens, 2004). Observation of the process of VHP approval in BAMI found the
procedure falling short in the key aspect it promised to address, namely speedy
approval across the participating countries. The VHP, too, was subject to regu-
latory regress and transformation, whilst BAMI has been undergoing repeated
re-approvals within its framework. This aspect cannot be detailed in this
article but it added to the overall complications faced in the implementation
of BAMI.
3. Methodology
We have been recording and analysing the eﬀects of European harmonization
policies on the BAMI adult stem cell clinical trial. Being a Principle Investigator
(PI) on the BAMI grant and project, Hauskeller has been observing BAMI from
the funding application to trial completion—now expected for 2019, two years
after the last patients will be recruited. Using interviews and mini-surveys
with team members, we collected a wide range of experiences and perspectives
from inside the large team. This article reports on the obstacles for trial
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implementation and day-to-day business that emerged after initial VHP
approval for the trial was gained in 2013.
Data collection began with a mini-survey to establish the attendees’ initial
views on the BAMI trial process at the BAMI ‘Kick-oﬀ Meeting’ in London,
where the sociology work package was introduced to the teams (primarily the
BAMI Consortium partners). A brief questionnaire was handed out to be
ﬁlled in then and there. The attendees were asked to reﬂect and list issues
with ethics approval encountered in previous trials, and to state whether they
expected any problems with approval for BAMI. Fourteen partners from eight
countries—Denmark, Spain, UK, Germany, Italy, Norway, Belgium and the
Czech Republic—were present. No respondent in this survey expected any pro-
blems with BAMI. Potential approval issues from other trials had been met and
solved locally. These local solutions were then discussed around the table,
because they would all have to be taken into consideration in the preparation
of the uniﬁed VHP approval for BAMI to ensure ready acceptance of the proto-
col by the national competent authorities.
In 2014/15, we conducted 28 interviews, 25 with clinical staﬀ (e.g. PIs, NCCs,
cardiologists, study nurses), and 3 with project managers responsible for trial-
wide infrastructure (insurance, centralized echo-cardiography, patient ran-
domization). Interviews lasted for 30 to 60 minutes, following a pre-deﬁned
topic guide. The interviews were recorded on tape and transcribed. At this
stage of BAMI the teams could report on their experiences with local implemen-
tation. Interviews were conducted face-to-face, via Skype or telephone.
As the BAMI partners were spread across Europe, interviewing via telephone
or Skype allowed for the collection of data when face-to-face interviewing was
not possible. It limited excessive travelling, with the consequent high cost in
researcher time and negative environmental eﬀect (Hanna, 2012). The little dis-
cussion on the use of Skype over telephone interviews presents arguments in
favour and against, referring to similar discussions contrasting telephone and
face-to-face interviews (Irvine et al., 2013; Oates, 2015).
An advantage of face-to-face interviews is that they oﬀer superior rapport with
the interviewee (Stephens, 2007; Holt, 2010) and thus possibly increased quality of
the collected data. Oates, however, found qualitative comparability and relevance
to the research questions between face-to-face and over-the-telephone data collec-
tion (2015). Carr andWorth (2001) point out that telephone interviews have fewer
pronounced face-to-face interviewer eﬀects—when the personality and behaviour
of the interviewer inﬂuence the behaviour and responses of the interviewee. In
contrast, Oates (2015) points out that telephone interviews tend to be shorter
with more requests for clariﬁcation from the researcher and more checks from
interviewees for adequacy in their responses. Consequently, as researchers we
expressed a preference for face-to-face interviews when feasible, but left the
choice between telephone or webcam enabled Skype to the interviewees, when
face-to-face interviews were not feasible.
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The interview questions were based on ﬁndings from the participant obser-
vation of regulatory approval processes and pilot interviews. Data collection
and analysis proceeded in parallel. Some initial ﬁndings required further data
collection and the return to early interviewees. Interview materials were tran-
scribed and the data analysed using conventional methods supported by
NVivo (Version 10). Keyword searches helped to identify themes and categories.
Entirely electronic-based analysis seemed unsuitable, not least because most
interviewees were not native speakers of English and might have used language
in non-standard ways. Also, some interviews had been conducted in other
languages (viz. German and Spanish) and we translated interview passages
that we used in publications.
Following analysis of the interview data, we used a ‘ﬁnding check’mini-survey
at a partner meeting on 12 February 2015 and forwarded it to BAMI team
members unable to attend, including study nurses. The aim was to collect
responses to, and validate our interpretation of, the ﬁndings hitherto. Twenty-
two respondents from nine countries commented in this format on how they
judged the relevance of our ﬁndings. The feedback conﬁrmed we had identiﬁed
all the problems of which respondents were aware, and at the same time it
showed an unexpected discrepancy in the assessment of the seriousness of the
diﬀerent problems. The dramatic eﬀects of the changes in the implementation
of the EU Directive on BAMI were agreed upon by all respondents.
With regard to the importance of the ﬁndings we describe in this article, we
note that respondents disagreed markedly on local cultural issues. Some of the
senior clinicians were not aware of them, others did not regard them as relevant
obstacles. Yet many clinical staﬀ at NCCs had highlighted these issues as major
hurdles with which they had struggled in the day-to-day running of the trial. The
study nurses in particular stressed how much time and money went into addres-
sing cultural expectations in relation to trial insurance, language and communi-
cation. This discrepancy in how PIs and NCC members rated the inﬂuence of
cultural issues will be considered after the relevant ﬁndings.
4. Cultural Issues
In this section we present our ﬁndings on the external factors or cultural diﬀer-
ences that cause problems and that have to be aligned with the overall regulatory
framework in which BAMI must operate. These cultural issues are obstacles that
aﬀect individual sites or countries and arise from their particular situations, con-
ventions or local regulations. They are not regulated in the EMA and VHP
approval procedures.
Situated outside direct EU clinical trial governance regimes, cultural diﬀer-
ences become more obvious and cause problems during the trial implementation
phase and in day-to-day conduct. They are confronted and solved by the staﬀ
running the trial in the clinic, i.e. primarily study nurses. Below we present
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examples of what we call cultural issues caused by local diﬀerences in practices
between European partner countries.
4.1. The GCP Certiﬁcate
According to the EU Directive 2001/20/EC, which is legally binding, anyone
working on a clinical trial needs to have the GCP certiﬁcate conﬁrming they
have passed a particular training module on the subject. The sponsor of
BAMI is in the UK, where it has become best clinical practice to expect that
the GCP module needs to be passed and the certiﬁcate re-issued every other
year for everyone conducting clinical trials. Whilst the certiﬁcate as such is
now compulsory across Europe, its biannual refresher is not. Yet, because
BAMI followed the ethical practices put forth by the UK sponsor, all partners
were formally compelled to comply with the UK practice of implementing the
EU GCP certiﬁcation.
Every clinical team member in BAMI had to present a GCP certiﬁcate dating
from within the past two years. This raised issues in three cases: two senior phys-
icians with many years of clinical and trial practice were requested to attend a
training module before their team was allowed to start in BAMI. The physicians
resisted for a while, arguing they were obviously GCP qualiﬁed—given their
experience—and thus did not need to do this: they eventually took the
module and obtained the certiﬁcate. In a third country, the PI was in possession
of a GCP certiﬁcate, dating from more than a decade ago and was reluctant to
comply with what seemed a mere formality. The resistance resulted in a delay
in some site initiations and was experienced as distressing by the study nurses
who had to convince the respective physicians to acquire the certiﬁcate by com-
pleting the online module provided by the sponsor. As sociologists we saw power
issues at play here, both among and within the clinical teams, and our interview
data support this interpretation—but as such this is not an original ﬁnding.
4.2. Insurance of the Patients in the Trial
When the PIs applied for ethics application through VHP, the worldwide insur-
ance policy with standard annual policy renewal was put in place at the sponsor-
ing lead institution, Queen Mary University of London. The trial was covered for
what is standard UK practice to run such a clinical trial in Europe and world-
wide. However, in the process of obtaining competent authority approval in
the partner countries, it became evident that diﬀerent countries within Europe
require additional local insurance because they have diﬀerent laws and traditions
regarding insurance policies that aﬀect clinical trial insurance.
In the UK it is common for many insurance companies in the private and
institutional sector to issue one-year insurance contracts, renewable annually.
In other partner countries, diﬀerent attitudes to how insurance ought to
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operate make good sense within their established framework. In Italy, for
example, university research hospitals fall into a special insurance category,
whereas non-university hospitals and their risks are classiﬁed separately:
In Italy we also had to sign extra insurance for the patients enrolled in the BAMI. And
actually, this is another issue that will come up shortly because in the insurance we
have covered the total number of patients that we enrol, that is 125, but what we
paid actually covers just one centre or university hospital, so we are now negotiating
the insurance because if we open satellite hospitals in the next months, although the
number of patients that we cover will be the same, it’s most likely that there will be
an increase in costs for us. The insurance will ask us to pay more, simply because
they are not qualiﬁed hospitals, I mean, like our hospital. So, there are some issues
that we are negotiating now. (NCC, Italy)
In Germany, the ethics committees argued that every patient needs to be
insured for as long as she or he is in the trial. Not least because, in case harm
is experienced by a patient, it might be extremely diﬃcult to get the trial insur-
ance renewed. The insurance provided for each patient has to cover the whole
period during which the patient is in the study. As this service was not provided
by the BAMI sponsor, the German team had to arrange its own insurance at a
cost of an additional €15,000 plus VAT for the ﬁrst 300 patients recruited.
Because of this high and unexpected cost, the German NCC has so far only
insured a smaller number of patients than they expect to recruit and will have
to add to the insurance in accordance with recruitment numbers.
The English patient insurance is totally insuﬃcient in Germany. The ethics committee
stated they cannot accept it, because in England insurance can be cancelled after one
year. The problem the German ethics committee has with this is that if an insurance
case were to happen, and subsequently no insurance company wanted to continue
insuring the trial, then the patients in BAMI would no longer be insured.… I then
agreed an additional insurance via the sponsor and the sponsor signed it. (PI, NCC,
Germany; translation CH)
Apart from the ﬁnancial burden, it seems that other connected issues would
have resulted in problems with insurance anyway, issues that can now be
addressed in the separate additional insurances set-up. The reason is that
there are other country-speciﬁc ethical requirements of insurance not covered
by the BAMI general insurance. Our interview analysis and a comparison of
Patient Information Sheets showed that, for example, in Spain, Italy and
Germany, patients have to be able to contact the insurance provider directly.
In the UK patients can contact the hospital trust where they were treated,
which would then contact the sponsor, and the sponsor would contact the
insurer. In Germany, Italy and Spain, good ethical practice requires that a
local oﬃce and phone number for the insurance covering the trial is on the
Patient Information Sheet so that patients can contact the company directly.
Again, there are diﬀerences in the details provided to trial participants. In
Germany the full postal address including telephone number and an email
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address have to be available to patients. The Spanish authorities, in contrast,
provide the number of the insurance policy and the name of the insurance
company, but no contact details. Instead, they encourage patients to get in
touch with the doctor in the ﬁrst instance. Documents originating in the UK
follow the standard National Health Service (NHS) complaints procedure,
directing patients to the Patient Advisory Liaison Service, for which there is
no direct equivalent in many other partner countries.
Increasing risk awareness also meant that many NCCs required the BAMI
insurance policy to be translated into their own language to be checked by
ethics authorities, something that comes at a cost. BAMI coordinating staﬀ at
Queen Mary University of London support NCCs in their eﬀorts to comply
with their particular insurance requirements. But they reported that it is often
hard for them to gauge what exactly needs to be done and to whom they
need to speak. Conversely, NCC staﬀ and PIs in the hospitals expect the team
at the sponsoring institution to know about these issues because they are not
experts in details of insurance either.
What needs to be insured and how patients are informed diﬀer across the
BAMI partner countries according to local cultural conventions and ethical per-
ceptions. Knowledge about these diﬀerences is not readily available within the
clinical research environment. Insurance issues and the other cultural issues
would not be confronted if the teams participated in a commercially sponsored
and funded trial. An industry sponsor would take on the task of ﬁguring out sol-
utions to insurance and other problems the clinical teams have had to solve in
BAMI, managing problems centrally with hired experts. Conducted by hospital
physicians without such a sponsor, the BAMI trial did not have a comparable
infrastructure of experts to fall back on. The unexpected problems arising
from these local diﬀerences have been described as disheartening at times by
some members in the clinical team.
4.3. Problems with Language Diversity
Several clinical trial nurses nominated language barriers as a big problem, par-
ticularly in hospitals in international cities such as Frankfurt, London, Rome and
Madrid, where many inhabitants and visitors do not speak the local language
suﬃciently well to communicate clearly in the acute clinical situation of an
AMI. Language issues are relevant in two contexts—informed consent pro-
cedures, and day-to-day communication—and as such have been not a central
but certainly a persistent topic in relation to clinical best practice (Betancourt
and Jacobs, 1972; Schenker et al., 2008).
Certainty about clear communication is required when establishing whether a
patient fully comprehends the trial and what they agree to participate in. In
order to ensure ethical conduct and informed consent, the clinical team must
judge the patient’s ability to consent. To give valid consent to participate,
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patients must not only possess the mental capacity to consent, but they must also
be suﬃciently informed about the trial and what it entails. They must be assured
that participation is voluntary and that declining does not aﬀect their treatment
negatively. Studies have shown that in stressful situations such as that following
a severe heart attack, patients’ cognitive function can be impaired to the extent
that they are unable to fully comprehend the details of a trial in which they are
asked to take part (Gammelgaard, 2004; Gammelgaard et al., 2004). This situ-
ation can be aggravated through language barriers (Howard and De Mets,
1981; Kucia and Horowitz, 2000).
For a multinational trial, a certain level of variety in patient languages
should be easily managed because Patient Information Sheets have been pre-
pared in all the primary languages of the countries participating. However,
the English language sheet cannot simply be used in Madrid, Rome or Frank-
furt because the content that needs to be covered diﬀers in response to local
ethical expectations, such as the insurance issue above. The Patient Infor-
mation Sheet of each country needs to be translated anew, at least in the diver-
ging sections. These translations must be carried out by a certiﬁed medical
translator, and in some countries the resulting document needs to be approved
by the relevant ethics committee. Therefore, recruiting patients who are not
conﬁdent speakers of the local language costs time and money. Nevertheless,
a study nurse we spoke to conﬁrmed that every eﬀort is made to include all eli-
gible patients in the trial.
The only problem is the language barrier. It’s always diﬃcult, if we don’t understand
the patients—we have to translate them, but of course, the patients are included in the
study.…We have a list (of interpreters), but actually, you ought to get consent in their
mother tongue. And you always have to ensure that the interpreter is neutral and
translates exactly what you are saying—you never know what they tell you and
whether they translate verbatim. I’d ﬁnd it helpful to have patient information
sheets in English. (Study Nurse, Germany; translation NB)
The second aspect concerns day-to-day communication with the patients
during the trial. Although the hospitals in the study have access to interpreters,
it has happened that patients cannot be included because they speak a language
for which no interpreter is available at short notice—and recruitment has to
happen within a day after standard AMI treatment.
If they do not speak the language, you cannot assess them properly and then also you
have to make sure that a family member is there with them to do the translation and
tell you how they feel. So, that’s why we found it very diﬃcult to recruit them… .
(Study Nurse, UK)
Interpreters also have to be in attendance at every check-up, which is usually
done over the phone. The logistical and ﬁnancial eﬀort involved because of
ethical and language requirements limits the recruitment of patients insuﬃ-
ciently versed in the local language.
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The regulatory and ethical approval-related problems in the everyday running
of a trial such as BAMI are manifold and vary between countries and even
between hospitals in a country. Yet the perception of these challenges, too,
varied amongst BAMI team members, markedly between senior cardiologist
PIs on the one hand and study nurses and country coordinating teams on the
other, as we found in our mini-survey where ﬁndings were checked by
participants.
Shared practice across a trial is required scientiﬁcally and harmonized regu-
lation across Europe aims to improve the conditions for rapid and reliable clini-
cal translation of stem cell science. Yet, alongside the equal position in which all
project partners have to work, cultural diﬀerences make themselves felt and
appear as local challenges to achieving this equal position whilst conforming
to local expectations. Diverse eﬀects of cultural diﬀerences in terms of ethical
or institutional practices appear when actions previously not formally standar-
dized become regulated in clinical trials. Diﬀerent societal institutions such as
insurance practices and cultural conventions aﬀect the smooth running of the
trial, given that the trial needs to balance two diﬀerent sets of expectations: har-
monized European standards and local necessities of doing things in a certain
way.
The most obvious problem for BAMI was the reclassiﬁcation of its particular
stem cell application under the rules for ATIMP. This required access to labora-
tories licensed to produce Investigative Medicinal Products to GMP standards,
which in 2011 was a relatively new and not widely available accredited
process. Problems with access to such laboratories locally meant that BAMI
had to cover the huge costs for transporting cells around Europe, again in a
manner conforming to ATIMP requirements. Less obvious problems arose fol-
lowing the BAMI team’s compliance with the EU’s VHP protocol.
Drawing on empirical data and the sociological literature on regulation, we
have illustrated what standardization in a non-standard world may mean, in
relation to the BAMI case study. We found that common practices across
many countries and cultures can be established by regulation and complied
with at this deﬁned standard level. However, the activities required to achieve
such harmonization of practice, confront a quagmire of diﬀerences between
practices in the clinics and countries participating in the standardization
process, which have to be re-arranged or modiﬁed in order to ﬁt. Cultural or
local diversity-related issues faced by the BAMI teams include insurance prac-
tices, how the relationship and contact between patients and the clinical team
are seen and managed, and how certainty about good communication can be
reached in multilingual settings.
The language barrier and its importance was perceived diﬀerently especially
in our mini-survey with BAMI teams to check their response to our ﬁndings
after analysis of the data we had collected. All the responding study nurses
regarded it as a major problem, i.e. they ‘strongly agree’ that language barriers
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hamper patient recruitment and therefore delay the trial. By contrast, for both
the PIs and national co-ordinators it was not an important issue. These
groups attribute the delay and recruitment issues to ﬁnancial constraints and
EU regulation.
[The] absence of commercial funding meant that all expertise had to be found in the
university, e.g. statistics, regulatory [expertise]. (PI 2, UK)
This quotation from one senior clinician in BAMI sums up similar statements
from several other clinician investigators. Others hinted that all problems in
BAMI could have been solved easily if much more money had been available.
In the speciﬁc context of BAMI with its small and closely interacting teams,
this discrepancy in perception of problems between nurses and senior manage-
ment staﬀ was an unexpected ﬁnding. On the one hand, nursing staﬀ perceived
‘external’ and cultural issues as requiring frequent decision-making and action,
whereas senior clinicians, on the other hand, thought that money could readily
solve such issues. The small sample size does not allow for a more detailed inves-
tigation of this point. Our interviews and observation provide only indications
that the division of labour and tasks between members of the trial teams and
the subsequent diﬀerences in their experiences of problems confronted in trial
conduct would form part of the explanation.
4.4. Attempts to Support Academic Clinical Trials in Europe
However, the problems from culturally diverse practices that have aﬀected
BAMI are likely to arise in other academic trials too. BAMI has been exception-
ally exposed to issues arising from regulatory change to harmonize practice
across Europe. The main reason is that the trial had been designed before the
described changes in European ATIMP regulation were established. The new
ATIMP regime came into force after the funding application for BAMI had
been submitted and by the time BAMI started, it had to be fully complied
with. BAMI is also the ﬁrst Phase III multinational trial that sought and
gained approval through VHP. One of the BAMI PIs explains this, citing the
insurance issue as an example:
… this is an EU problem. The sponsor normally takes on the insurance responsibility,
which we do, but each country has been told by their local [competent authority
issuing ethical approval] that they have to get local insurance too. And again it’s a
real shame because the only people that are beneﬁtting are the insurance companies.
The study suﬀered because this is extra money that we didn’t think we needed. I don’t
see how the patients beneﬁt any more [from being] protected both ways. So, again, it’s
not particularly geared to facilitating this research. One could argue that, obviously, I
have got a very cynical viewpoint because it has been so diﬃcult. But it’s simply that,
you know, there’s the information that we needed to plan for—it was just not available.
We don’t have an infrastructure that feeds into us. An industry would outsource the
whole review to make sure they knew what was coming. (PI 1, UK)
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In order to support clinical teams in clinical trial research, when the pro-
blems they would encounter in the new regulatory set-up became apparent,
The European Commission funded several long- and short-term projects to
support pharmaceutical innovation. One of them was the AGORA project,
led by University College London from 2013 to 2015. The acronym stands
for ATMP GMP Open Access Research Alliance. AGORA aimed at addressing
the problems academic research consortia encounter working eﬀectively within
the EU regulatory clinical trial framework. The vision was an institutional mul-
tinational academic platform in order to bundle and provide to other teams the
information needed to run clinical trials in compliance with EU regulations
and Directives across multiple country settings. The AGORA4 project orga-
nized several workshops and events to that eﬀect. The account in their end
of award report (AGORA, 2016) captures the key problems BAMI faced,
and potential solutions were envisaged:
The aim of this project was to undertake a series of speciﬁc actions to address each of
the current unmet needs and critical issues arising from our previous FP7 Academic
Good Manufacturing Practice (GMP) study on the development and delivery of
new advanced therapies for the treatment of cancers and regenerative medicine… .
AGORA planned to create a resource to boost biomedical and clinical research
through provision of a platform to facilitate consultation with biomedical researchers
in the ﬁeld. Recent EC actions have attempted to ensure the development, provision
and free movement of ATMPs within the EU. However, FP7-funded research found
substantial heterogeneity in the regulatory practice across member states which is
leading to confusion and uncertainty and creating a severe barrier to development
and delivery of these novel medicines which was weakening the position of EU aca-
demics and industry to collaborate and compete globally in this expanding ﬁeld.
The outcome of the current impact assessment by ‘Academic GMP’ did not conclude
that the current EU legislation needed revision but that a framework of support and
training was needed to facilitate the implementation.
However, AGORA explicitly aimed to foster phase I and phase II clinical trials
in hospital environments to prepare the ground for industry-sponsored phase III
trials. Being an academic phase III trial, BAMI is one of the FP 7 projects that
provide ample evidence of the need for infrastructure of the sort at which
AGORA aimed. But BAMI itself could not ﬁnd support there, not least
because it started years before the platform was established. Concerning the
future, it is also notable that the AGORA project ended in 2015 and it is an
open question as to how long their informative website will remain accessible.
In the autumn of 2016 its website agora-gmp.org contained a farewell letter,
summarizing its achievements.
5. Conclusion
Beyond the internal issues of the BAMI5 multinational clinical trial—including
the quality and feasibility of the medical intervention, and the set-up and
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implementation of the trial following harmonized safety, security and ethics pro-
tocols—there are a range of external challenges to everyday practice which costs
time and money to solve. Our ﬁndings give a detailed account of the complexity
of conducting such a trial. They show that the clinical work is multifaceted and
closely intertwined with ‘external’ cultural practices and conventions.
In the introduction to this article we set out to address three questions. They
have been answered empirically in relation to the speciﬁc case, as we have shown
how the common EU regulatory set-up has aﬀected trial conduct and which
speciﬁc implications and unexpected challenges the national teams had to over-
come in order to comply with both local expectations and EU standardized pro-
tocols. The third question, how cultural diﬀerence have aﬀected BAMI as a
clinical trial, has also been touched upon, but it will now be answered in more
detail and serve as a starting point for our theoretical discussion of what the
ﬁndings from this project may mean for the sociology of standardization.
A major practical accomplishment has been the adaptation to the local cultural
rules in such a way that they achieve full compliance with harmonized regulations.
For the sociology of standards and regulation this means that whilst harmoniza-
tion demands creative solutions and ﬁnancial support, it can often be achieved
without substantial changes to cultural practices. Our ﬁndings respond to the chal-
lenge by Timmermans and Epstein (2010) to study in detail the eﬀects of stan-
dards and regulations. Timmermans and Epstein’s review is entitled ‘A World
of Standards but not a Standard World’ (2010). They argue that ‘each standard
achieves some small or large transformation of an existing social order’ (p. 83)
and that ‘the speciﬁcity of the actual standard matters: Diﬀerent standards will
generate diﬀerent outcomes for diﬀerent users’ (2010). ‘Rather than making any
totalizing claims about the nature or eﬀects of these phenomena, we argue that
their sociological import comes out most clearly through scholarship that is
speciﬁc, empirical and located in concrete social settings’ (p. 84).
Necessarily case-speciﬁc to regenerative medicine clinical trials, the ﬁndings
should allow comparison between this new area of extensive and investment-
heavy standard creation and ﬁndings from other areas of technical standardiz-
ation. The speciﬁcity of the ﬁndings reported above allows us to make prominent
points of wider sociological relevance. Firstly, the ﬁndings add substance to dis-
cussions on the implementation of the standards and show that the practices
involved can be viewed and experienced diﬀerently by diﬀerent practitioners
depending on their professional role and wider social and regulatory environ-
ment. Secondly, it shows that practically applying new standards often confronts
the practitioners with new insights into micro-level diﬀerences in practice that
had seemed the same before, and it illustrates just how tightly speciﬁc ways of
doing things are tied up and interwoven with multiple other conventional
ways of doing things. Thirdly, the changes required by new regulations are
undertaken in such a way that they have little impact on related and surrounding
practices and expectations as possible.
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Our ﬁndings infer that the ﬁeld of clinical practice is sensitive to engrained
values and beliefs about patient rights and GCP that are touched by changes
in everyday routines. At the same time, standardization as prerequisite to bring-
ing new therapeutic techniques to a large patient population has become a key
area of the current political economy in Europe. It may be helpful for scholars in
the sociology of standards to consider those diﬀerent aspects and compare
ﬁndings in other studies according to these parameters to remain empirically
speciﬁc, as Timmermans and Epstein demand, whilst sharing relevant dimen-
sions for comparisons between ﬁndings from diﬀerent areas of standardization.
To add more substance from our project to such a comparative discussion, we
consider our ﬁndings regarding both the division of labour in the BAMI trial and
its eﬀects on how interviewees assess the new regulatory regime, and the invest-
ment dimension—again from the point of view of our subset of actors in regen-
erative medicine, who identify ambiguous eﬀects of those standards on the ﬁeld
of regenerative medicine depending on the types of stem cells used.
BAMI team members in diﬀerent roles evaluated the set of problems
described diﬀerently. For example, there is a discrepancy between nurses and
doctors in the day-to-day conduct of the trial, who rate cultural issues such as
language as important problems, and the clinician scientist PIs, who predomi-
nantly see these cultural issues as minor problems aﬀecting the team mostly
because of the ﬁnancial constraints in publicly funded research. The NCCs6
and trial nurses also reported that in industry-funded trials these problems
would be solved centrally by the funder. The ways in which diﬀerent BAMI
actors perceived the challenges encountered, and ranked them in severity, also
highlight the diversity of eﬀect any standardization has on its diﬀerent users.
The discrepancy in evaluating the prominence of these problems highlights
two key points for the wider debate on biomedical and technical regulations
and their eﬀects.
Firstly, whilst not facing the daily brunt of these issues, and thus at ﬁrst glance
seeming detached or even under-appreciative, the BAMI PIs’ argument that
most problems could be resolved with money has a science-policy dimension
that needs to be pointed out clearly. According to them, expanding ATIMP
(ATIMP) regulation to also cover treatments such as autologous adult stem
cell therapies eﬀectively disadvantages clinician-led research in regenerative
medicine. The kind of stem cell therapy BAMI represents is seen as clinically
promising by these experts (Mathur et al., 2017), but as unrewarding from an
industry point of view. The procedure used in BAMI is not patentable and
thus industry interest in developing and trialling it is lacking. BAMI has to
make do with six million Euros awarded by the European Commission and
no substantial additional industry support. Without the additional major costs
arising from the streamlined regulation aﬀecting BAMI, however, the cost-cal-
culation that six million Euros would suﬃce to conduct this phase III clinical
trial was credible when the funding application was put together in 2010.
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The streamlining of all stem cell therapies under ATIMP on the one hand,
which massively increases costs, and the lack of economic incentive for indus-
trial sponsors to engage in autologous tissue repair research on the other,
mean that the regulatory apparatus imposes an obstacle for this line of research.
Money can overcome the issues BAMI faces—but in the public research sector
this money is not available or oﬀered. Thus, some of the PIs criticize recent
European regulatory changes, because they see them as eﬀectively inﬂuencing
which stem cell research can go ahead, favouring particular forms of stem cell
research over others without any scientiﬁcally or clinically valid reasons for
that imbalance.
Secondly, cultural diﬀerences are endemic and thus standardization always
risks creating new sets of problems. While the frequent complications in day-
to-day work and the ﬁnancial limitations to solving problems have occasionally
frustrated BAMI team members, they have highlighted to us as social scientists
the intersection of diﬀerent perceptions and routines that have evolved around
patient autonomy, quality assurance and medical research. The cultural issues
described indicate a web of culturally speciﬁc and embedded routine practices
that involve a range of diﬀerent institutions and contexts in which local clinical
teams operate.
The harmonization standards that had to be complied with in BAMI have dis-
rupted some threads in this web, and the teams struggle with how to repair the
tears in the peculiar local fabric of interactions between insurance conventions,
ethical expectation, patient autonomy and consent and so on. The clinical staﬀ in
BAMI, NCCs especially, have learned a lot about the particularities of their own
national systems of rules and cultural expectations, because they have had to
align their practice with the harmonized rules for the whole multinational
trial, and without industry experts who otherwise could take over the manage-
ment of such issues. The experience may foster more independence from indus-
trial sponsors and increase international collaborative spirit among clinical
teams, if support infrastructures for academic biomedical sciences are built up
—as was envisaged on a limited scale with AGORA.7
Advancing regenerative medicine in Europe with academic research that
pursues treatment routes that do not attract major industry sponsorship
seems to require a much stronger support infrastructure. Our ﬁndings, com-
bined with the existing problem descriptions from AGORA, suggest that a
central institution would be needed, which bundles the varied and specialist
expertise needed to implement a multinational trial accessible to publicly
funded research-active cooperating clinical teams in Europe, providing services
equivalent to those provided behind the scenes by industrial sponsors to clinical
research teams. Currently, in phase III clinical trials, each team has to struggle
through a maze of cultural and regulatory challenges. An accessible expert
centre would provide a more level playing ﬁeld between approaches to new
therapies that promise better patient health without promising great ﬁnancial
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rewards, and those that oﬀer the latter too. It would also save resources, both
monetary and motivational, for fostering a successful European clinical research
community.
Collectively our ﬁndings demonstrate the problems harmonization creates
when new standardized rules must be brokered against varied and distinctive
cultural expectations and institutional practices—many of which are outside
the trial protocol but aﬀect clinical routine actions on a daily basis.
Notes
1. An abbreviation for: ‘The eﬀect of intracoronary reinfusion of bone marrow-derived
mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction’.
BAMI is a Phase III clinical trial led by clinician scientists and funded by the European
Commission’s FP 7 Health programme.
2. Largely due to standardization by medical organizations, treatment of AMI follows
best practice guidelines set out by the European Society of Cardiology.
3. The beneﬁts of standardization according to the European Commission webpages,
available at: http://ec.europa.eu/growth/single-market/european-standards/policy/
beneﬁts/index_en.htm (accessed 30 May 2016).
4. AGORA stands for ‘Advanced Therapy Medicinal Product Good Manufacturing Prac-
tice Open Access Research Alliance’.
5. An abbreviation for: ‘The eﬀect of intracoronary reinfusion of bone marrow-derived
mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction’.
BAMI is a Phase III clinical trial led by clinician scientists and funded by the European
Commission’s FP 7 Health programme.
6. NCC stands for National Coordinating Centre staﬀ. In each country one hospital leads
the trial in that country. The NCC recruits, contracts and assesses the work at other
satellite hospitals that also recruit patients to BAMI.
7. AGORA stands for ‘Advanced Therapy Medicinal Product Good Manufacturing Prac-
tice Open Access Research Alliance’.
Acknowledgements
This research was supported by the dedication of the BAMI team and with the help of the
BAMI Coordinator, Anthony Mathur and Sheik Dowlut at the BAMI Trial Oﬃce. We
wish to thank the anonymous reviewers of earlier versions of this article, and also Achim
Rosemann, Les Levidow and colleagues at Exeter University, especially Susan Kelly, who pro-
vided valuable feedback to earlier versions of this article.
Disclosure Statement
No potential conﬂict of interest was reported by the authors.
Funding
The BAMI Project is partially funded by the European Commission under the 7th Frame-
work Programme (Grant agreement number 278967).
SCIENCE AS CULTURE 195
References
AGORA (2016) Final Report Summary AGORA, Accessible Online at Community Research
and Development Information Service. Available at http://cordis.europa.eu/result/rcn/
177747_en.html (accessed 18 June 2016).
Anderson, D. (2003) The patient recruitment market. An overview of today’s issues, Applied
Clinical Trials, November 2. Available at http://www.appliedclinicaltrialsonline.com/
patient-recruitment-market (accessed 18 August 2016).
Anele, D. I. O. (2006) Nigeria’s health care delivery system and recent biomedical technol-
ogies: A critical survey, in: W. Bender, C. Hauskeller, and A. Manzei (Eds) Crossing
Borders Cultural, Religious, and Political Diﬀerences Concerning Stem Cell Research. A
Global Approach, pp. 207–224 (Muenster: Agenda Publishers).
Baeyens, A. (2004) Impact of the European Clinical Trials Directive on academic clinical
research, Med Law, 23, pp. 103–110.
Beltrame, L. (2014) The therapeutic promise of pluripotency and its political use in the Italian
stem cell debate, Science as Culture, 23(4), pp. 493–516.
Bender, W., Hauskeller, C., and Manzei, A. (Eds.) (2005) Crossing Borders: Cultural, Religious
and Political Diﬀerences Concerning Stem Cell Research: A Global Approach (Muenster:
Agenda Publishers).
Betancourt, J. R. and Jacobs, E. A. (1972) Language barriers to informed consent and conﬁ-
dentiality: The impact on women’s health, Journal of American Medical Women’s
Association, 55(5), pp. 294–295.
Bowker, G. and Star, S. L. (1999) Sorting Things Out (Cambridge, MA: MIT Press).
Cambrosio, A., Keating, P., Schlich, T., and Weisz, G. (2006) Regulatory objectivity and the
generation and management of evidence in medicine, Social Science & Medicine, 63, pp.
189–199.
Cambrosio, A., Keating, P., Schlich, T., and Weisz, G. (2009) Biomedical conventions and
regulatory objectivity: A few introductory remarks, Social Studies of Science, 39, pp.
651–664.
Campbell, D. T. and Stanley, J. C. (1963) Experimental and quasi-experimental designs for
research, in: N. L. Gage (Ed) Handbook of Research on Teaching, pp. 171–246
(Chicago: Rand McNally).
Carr, E. C. J. and Worth, A. (2001) The use of the telephone interview for research, Nursing
Times Research, 6(1), pp. 511–524.
Cartwright, N. (2007) Are RCTs the gold standard? BioSocieties, 2, pp. 11–20.
Castel, P. (2009) What’s behind a guideline? Authority, competition and collaboration in the
French oncology sector, Social Studies of Science, 39, pp. 743–764.
Cressy, D. (2010) UK doctors demand research reform, Nature News, May 17. doi:10.1038/
news.2010.246.
Epstein, S. (2007) Inclusion: The Politics of Diﬀerence in Medical Research (Chicago: The
University of Chicago Press).
European Commission (2001) Directive 2001/20/EC of the European Parliament and of the
Council of 4 April 2001. Oﬃcial Journal of the European Communities, May 1, L 121/3M4.
European Commission (2004) Directive 2004/23/EC of the European Parliament and of
the Council of 31 March 2004. Oﬃcial Journal of the European Communities, April
7, L 102/48.
European Commission (2009) Assessment of the Functioning of the ’Clinical Trials
Directive’ 2001/20/EC. Public consultation paper. Available at http://ec.europa.eu/
health//sites/health/ﬁles/ﬁles/clinicaltrials/docs/2009_10_09_public-consultation-paper.
pdf (accessed 30 June 2017).
196 C. HAUSKELLER ET AL.
European Commission (2016) Growth, Internal Market, Industry, Entrepreneurship and
SMES: Beneﬁt of Standards. Available at http://ec.europa.eu/growth/single-market/
european-standards/policy/beneﬁts/index_en.htm (accessed 30 May 2016).
European Commission and European Medicines Agency (2007) European Commission –
European Medicines Agency Conference on the Operation of the Clinical Trials.
Faulkner, A., Geesink, I., Kent, J., and Fitzpatrick, D. (2008) Tissue-engineered technologies:
Scientiﬁc biomedicine, frames of risk and regulatory regime-building in Europe, Science as
Culture, 17(2), pp. 195–222.
Gammelgaard, A. (2004) Patients’ perceptions of informed consent in acute myocardial
infarction research: A questionnaire based survey of the consent process in the
DANAMI-2 trial, Heart, 90, pp. 1124–1128.
Gammelgaard, A., Rossel, P., Mortensen, O. S. (2004) Patients’ perceptions of informed
consent in acute myocardial infarction research: A Danish study, Social Science &
Medicine, 58, pp. 2313–2324.
Garattini, S. (European Commission) (2009) Can we facilitate multinational investigator-
driven trials? Available at http://ec.europa.eu/health/ﬁles/clinicaltrials/docs/responses_
2001-20/european_science_foundation_3.pdf (accessed 18 June 2016).
Hanna, P. (2012) Using internet technologies (such as Skype) as a research medium: A
research note, Qualitative Research, 12(2), pp. 239–242.
Hartmann, M. (2012) Impact assessment of the European clinical trials directive: A longi-
tudinal, prospective, observational study analysing patterns and trends in clinical drug
trial applications submitted since 2001 to regulatory agencies in six EU countries,
Trials, 13, p. 816.
Hartmann, M. and Hartmann-Vareilles, F. (2006) The Clinical Trials Directive: How is it
aﬀecting Europe’s noncommercial research, PLoS Clinical Trials, 1, p. e13.
Hauskeller, C. and Baur, N. (2017) Travelling cells – harmonized European regulation and
the BAMI stem cell trial, in: P. Van Pham and A. Rosemann (Eds) Stem Cells in
Clinical Application. Safety, Ethics and Regulation (Singapore: Springer).
Hogle, L. (2009) Pragmatic objectivity and the standardization of engineered tissues, Social
Studies of Science, 39, pp. 717–742.
Hollak, C. E. M., Biegstraten, M., Baumgartner, M. R., Belmatoug, N., Bembi, B., Bosch, A.,
Brouwers, M., Dekker, H., Dobbelaere, D., Engelen, M., Groenendijk, M. C., Lachmann, R.,
Langendonk, J. G., Langeveld, M., Linthorst, G., Morava, E., Poll-The, B. T., Rahman, S.,
Rubio-Gozalbo, M. E., Spiekerkoetter, U., Treacy, E., Wanders, R., Zschocke, J., and
Hagendijk, R. (2016) Position statement on the role of healthcare professionals, patient
organizations and industry in European Reference Networks, Orphanet Journal of Rare
Diseases, 1, pp. 1–11. Available at http://hdl.handle.net/11245/1.510979 (accessed 21
August 2016).
Holt, A. (2010) Using the telephone for narrative interviewing: A research note, Qualitative
Research, 10(1), pp. 113–121.
Howard, D. and DeMets, D. (1981) How informed is informed consent? Controlled Clinical
Trials, 2, pp. 287–303.
Hunter, P. (2011) The health of European medical research, European Molecular Biology
Organization Reports, 12, pp. 110–112.
Irvine, A., Drew, P., and Sainsbury, R. (2013) ‘Am I not answering your questions properly?’
Clariﬁcation, adequacy and responsiveness in semi-structured telephone and face-to-face
interviews, Qualitative Research, 13(1), pp. 87–106.
Jasanoﬀ, S. (2005) Designs on Nature: Science and Democracy in Europe and the United States
(Princeton, NJ: Princeton University Press).
SCIENCE AS CULTURE 197
Kucia, A. and Horowitz, J. (2000) Is informed consent to clinical trials an ‘upside selective’
process in acute coronary syndromes? American Heart Journal, 140, pp. 94–97.
Lampland, M. and Star, S. L. (eds.) (2009) Standards and Their Stories: How Quantifying,
Classifying and Formalizing Practices Shape Everyday Life (Ithaca, NY: Cornell
University Press).
Lemaire, F. and Baeyens, A. (2002) Clinical research: A European Union directive, Intensive
Care Medicine, 28, p. 660.
Mathur, A., Aviles, F., Dimmeler, S., Hauskeller, C., Janssens, S., Menasche, P., Wojakowski,
W., Martin, J. F., and Zeiher, A. (2017) The consensus of the Task Force of the European
Society of Cardiology concerning the clinical investigation of the use of autologous adult
stem cells for the treatment of acute myocardial infarction and heart failure – update 2016,
European Heart Journal, doi:10.1093/eurheartj/ehw640.
Nwobike, J. (2006) Pharmaceutical Corporations and access to drugs in developing countries:
The way forward, 4 Sur, International Journal on Human Rights, 3(4), pp. 127–143.
Oates, J. (2015) Use of Skype in interviews: The impact of the medium in a study of mental
health nurses, Nurse Researcher, 22(40), pp. 13–17.
Petryna, A. (2009) When Experiments Travel: Clinical Trials and the Global Search for
Human Subjects (Princeton, NJ: Princeton University Press).
Rosemann, A. and Sleeboom-Faulkner, M. (2016) New regulation for clinical stem cell
research in China: Expected impact and challenges for implementation, Regenerative
Medicine, 11(1), pp. 5–9.
Rothwell, P. (2005) Treating individuals. External validity of randomized controlled trials:
‘To whom do the results of this trial apply’? The Lancet, 365, pp. 82–93.
Salter, B. (2007) Bioethics and the global moral economy: The cultural politics of human
embryonic stem cell science, Science, Technology and Human Values, 32(5), pp.
554–581.
Salter, B. and Salter, C. (2013) Bioethical ambition, political opportunity and the European
governance of patenting: The case of human embryonic stem cell science, Social Science
and Medicine, 98, pp. 286–292.
Salter, B., Zhou, Y., and Datta, S. (2014) Making choices: Health consumers, markets and the
global stem cell therapy market, BioDrugs, 28, pp. 461–464.
Schenker, Y., Lo, B., Ettinger, K. M., and Fernandez, A. (2008) Navigating language barriers
under diﬃcult circumstances, Annals of Internal Medicine, 149(4), pp. 264–269.
Star, S. L. (1991) Power, technologies and the phenomenology of conventions: On being
allergic to onions, in: J. Law (Ed) A Sociology of Monsters: Essays on Power, Technology
and Domination, pp. 26–56 (London: Routledge).
Star, S. L. (1995) The politics of formal representations: Wizards, gurus and organizational
complexity, in: S. L. Star (Ed) Ecologies of Knowledge: Work and Politics in Science and
Technology, pp. 88–118 (Albany, NY: State University Press).
Stephens, N. (2007) Collecting data from elites and ultra elites: Telephone and face-to-face
interviews with macroeconomists, Qualitative Research, 7(20), pp. 203–216.
Stephens, N., Lewis, J., and Atkinson, P. (2013) Closing the regulatory regress: GMP accred-
itation in stem cell laboratories, Sociology of Health and Illness, 35(3), pp. 345–360.
Sunder Rajan, K. (2010) The experimental machinery of global clinical trials: Case studies
from India, in: A. Ong and N. Chen (Eds) Asian Biotech: Ethics and Communities of
Fate, pp. 55–80 (Durham, NC: Duke University Press).
Timmermans, S. and Epstein, S. (2010) A world of standards but not a standard world:
Toward a sociology of standards and standardization, Annual Review of Sociology, 36,
pp. 69–89.
198 C. HAUSKELLER ET AL.
Veerus, P., Lexchin, J., and Hemminki, E. (2014) Legislative regulation and ethical govern-
ance of medical research in diﬀerent European Union countries, Journal of Medical
Ethics, 40(6), pp. 409–413.
Waldby, C. and Salter, B. (2008). Global governance in human embryonic stem cell science:
Standardization and bioethics in research and patenting, Studies in Ethics, Law, and
Technology, 2(1), pp. 1–23.
Weber, S., Wilson-Kovacs, D., and Hauskeller, C. (2010) The regulation of stem cell thera-
pies: Comparing the UK and Germany, in: C. Lenk et al. (Eds.) Human Tissue
Research, pp. 159–167 (Oxford: Oxford University Press).
Will, C. (2007) The alchemy of clinical trials, BioSocieties, 2, pp. 85–99.
Will, C. and Moreira, T. (2010)Medical Proofs, Social Experiments. Clinical Trials in Shifting
Contexts (Farnham: Ashgate).
Wilson-Kovacs, D., Weber, S., and Hauskeller, C. (2010) Stem cells clinical trials for cardiac
repair: Regulation as practical accomplishment, Sociology of Health and Illness, 32(1), pp.
89–105.
SCIENCE AS CULTURE 199
